Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07944430

Clinician-Selected FSH Starting Dose and Mature Oocyte Yield in Predicted Poor Responders

Sponsor: American Hospital 2 Kosovo

View on ClinicalTrials.gov

Summary

This is a single-centre, prospective, non-interventional (observational) cohort study examining the association between the clinician-selected starting dose of follicle-stimulating hormone (FSH) and the yield of mature metaphase II (MII) oocytes in women with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number \[POSEIDON\] group 3 or 4) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. The FSH dose is chosen by the treating physician as part of routine care; the study does not allocate, randomize, or change treatment. The primary outcome is the number of MII oocytes per initiated index cycle. Because dosing is not randomized, analyses are adjusted for measured confounders and address confounding by indication.

Official title: Association of Clinician-Selected FSH Starting Dose With Mature Oocyte Yield in Women With Predicted Poor Ovarian Response: The OPTIMAL-DOSE Prospective Cohort Study

Key Details

Gender

FEMALE

Age Range

18 Years - 42 Years

Study Type

OBSERVATIONAL

Enrollment

160

Start Date

2026-11

Completion Date

2029-08

Last Updated

2026-11-18

Healthy Volunteers

No

Interventions

DRUG

Follicle-stimulating hormone (FSH)

FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

Locations (1)

American Hospital Kosova

Pristina, Kosovo